Major

Biology

Research Abstract

The nuclear hormone receptor DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) is associated with the development and progression of prostate cancer within human males. Previous studies on DAX-1 have suggested a repression of steroidogenesis, indicating an inverse correlation between DAX-1 and steroidogenic gene expressions. To further understand the role of DAX-1 in tumor growth and development, experimentation was performed on Androgen Receptor (AR) sensitive and insensitive prostate cancer cell lines. Analysis of the different gene expression patterns of prostate cancer cell lines (including a CRISPR DAX-1 negative cell line) under separate treatment conditions, provides conclusive data regarding the link between DAX-1 and AR. The utilization of the DAX-1 negative cell line has also permitted the opportunity to develop a better understanding of advanced stage prostate cancer by simulating its inability to express the DAX-1 gene. The collected data on the relationship between DAX-1 and AR may aid in further studies to identify additional targets for the treatment of prostate cancer.

Faculty Mentor/Advisor

Dr. Christina Tzagarakis-Foster

Share

COinS
 
Apr 27th, 10:00 AM Apr 27th, 3:00 AM

DAX-1 Gene Expression Regulation in Prostate Cancer Cells through the Activation of Androgen Receptors

The nuclear hormone receptor DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) is associated with the development and progression of prostate cancer within human males. Previous studies on DAX-1 have suggested a repression of steroidogenesis, indicating an inverse correlation between DAX-1 and steroidogenic gene expressions. To further understand the role of DAX-1 in tumor growth and development, experimentation was performed on Androgen Receptor (AR) sensitive and insensitive prostate cancer cell lines. Analysis of the different gene expression patterns of prostate cancer cell lines (including a CRISPR DAX-1 negative cell line) under separate treatment conditions, provides conclusive data regarding the link between DAX-1 and AR. The utilization of the DAX-1 negative cell line has also permitted the opportunity to develop a better understanding of advanced stage prostate cancer by simulating its inability to express the DAX-1 gene. The collected data on the relationship between DAX-1 and AR may aid in further studies to identify additional targets for the treatment of prostate cancer.